Impact of relative cisplatin dose to skeletal muscle mass on adverse events in patients with head and neck cancer undergoing chemoradiotherapy.
Satoshi SuzukiTomoya YokotaAkifumi NotsuSatoshi HamauchiYusuke OnozawaKunihiro FushikiKotoe OshimaTakeshi KawakamiTakahiro TsushimaHirofumi YasuiHirofumi OgawaTsuyoshi OnoeKeisuke KawataniKentaro YamazakiPublished in: The oncologist (2024)
The CDDP index based on C3-SMM was an independent predictive factor for grade ≥ 3 CDDP-related AEs. C3-SMM is potentially more useful than BSA for determining the optimal CDDP dose in patients with HNSCC.